Total words: 2097 | 2-word phrases: 547 | 3-word phrases: 592 | 4-word phrases: 614
| Title | Try to keep the title under 60 characters (26 characters) Vertex Ventures Healthcare |
| Description | Try to keep the meta description between 50 - 160 characters (144 characters) Vertex Ventures HC is a healthcare and life sciences VC fund investing across medical devices, biotech, diagnostics and digital health services. |
| Keywords | Meta keywords are not recommended anymore (0 characters) |
| H1 | H1 tag on the page (34 characters) Building Next Generation Medicines |
| # | Keyword | H1 | Title | Des | Volume | Position | Suggest | Frequency | Density |
|---|---|---|---|---|---|---|---|---|---|
| 1 | visit | 25 | 7.27% | ||||||
| 2 | website | 25 | 7.27% | ||||||
| 3 | to | 21 | 6.10% | ||||||
| 4 | and | 18 | 5.23% | ||||||
| 5 | of | 17 | 4.94% | ||||||
| 6 | more | 16 | 4.65% | ||||||
| 7 | read | 14 | 4.07% | ||||||
| 8 | 2024 | 14 | 4.07% | ||||||
| 9 | may | 14 | 4.07% | ||||||
| 10 | authorlogo | 14 | 4.07% |
| # | URL | Whois | Check |
|---|---|---|---|
| 1 | https://vertexventures.com/us | Whois | vertexventures.com |
| 2 | https://vertexventures.cn/ | Whois | vertexventures.cn |
| 3 | https://www.vertexventures.co.il/ | Whois | co.il |
| 4 | https://vertexventures.jp/en | Whois | vertexventures.jp |
| 5 | https://www.vertexventures.sg/ | Whois | vertexventures.sg |
| 6 | https://vertexgrowth.com/ | Whois | vertexgrowth.com |
| 7 | https://ir.neumoratx.com/news-releases/news-release-details/neumora-therapeutics-announces-initiation-phase-2-study | Whois | neumoratx.com |
| 8 | https://ir.neumoratx.com/news-releases/news-release-details/neumora-therapeutics-announces-initiation-phase-2-study | Whois | neumoratx.com |
| 9 | https://elevate.bio/press-releases/elevatebio-announces-new-u-s-patents-for-lead-life-edit-crispr-systems-and-adenine-deaminases-enabling-advanced-gene-editing-techniques/ | Whois | elevate.bio |
| 10 | https://elevate.bio/press-releases/elevatebio-announces-new-u-s-patents-for-lead-life-edit-crispr-systems-and-adenine-deaminases-enabling-advanced-gene-editing-techniques/ | Whois | elevate.bio |
| 11 | https://eyebiotech.com/merck-to-acquire-eyebio/ | Whois | eyebiotech.com |
| 12 | https://eyebiotech.com/merck-to-acquire-eyebio/ | Whois | eyebiotech.com |
| 13 | https://obsidiantx.com/news-releases/obsidian-therapeutics-announces-positive-clinical-data-from-obx-115-in-patients-with-advanced-melanoma-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting/ | Whois | obsidiantx.com |
| 14 | https://obsidiantx.com/news-releases/obsidian-therapeutics-announces-positive-clinical-data-from-obx-115-in-patients-with-advanced-melanoma-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting/ | Whois | obsidiantx.com |
| 15 | https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-announces-555-million-private-placement | Whois | bicycletherapeutics.com |
| 16 | https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-announces-555-million-private-placement | Whois | bicycletherapeutics.com |
| 17 | https://www.businesswire.com/news/home/20240521592452/en/Indapta-Therapeutics-Awarded-4.5-Million-by-CPRIT-to-Advance-Clinical-Development-of-its-Allogenic-Natural-Killer-Cell-Therapy | Whois | businesswire.com |
| 18 | https://www.businesswire.com/news/home/20240521592452/en/Indapta-Therapeutics-Awarded-4.5-Million-by-CPRIT-to-Advance-Clinical-Development-of-its-Allogenic-Natural-Killer-Cell-Therapy | Whois | businesswire.com |
| 19 | https://ir.neumoratx.com/news-releases/news-release-details/neumora-therapeutics-announces-initiation-phase-2-study | Whois | neumoratx.com |
| 20 | https://ir.neumoratx.com/news-releases/news-release-details/neumora-therapeutics-announces-initiation-phase-2-study | Whois | neumoratx.com |
| 21 | https://elevate.bio/press-releases/elevatebio-announces-new-u-s-patents-for-lead-life-edit-crispr-systems-and-adenine-deaminases-enabling-advanced-gene-editing-techniques/ | Whois | elevate.bio |
| 22 | https://elevate.bio/press-releases/elevatebio-announces-new-u-s-patents-for-lead-life-edit-crispr-systems-and-adenine-deaminases-enabling-advanced-gene-editing-techniques/ | Whois | elevate.bio |
| 23 | https://eyebiotech.com/merck-to-acquire-eyebio/ | Whois | eyebiotech.com |
| 24 | https://eyebiotech.com/merck-to-acquire-eyebio/ | Whois | eyebiotech.com |
| 25 | https://obsidiantx.com/news-releases/obsidian-therapeutics-announces-positive-clinical-data-from-obx-115-in-patients-with-advanced-melanoma-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting/ | Whois | obsidiantx.com |
| 26 | https://obsidiantx.com/news-releases/obsidian-therapeutics-announces-positive-clinical-data-from-obx-115-in-patients-with-advanced-melanoma-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting/ | Whois | obsidiantx.com |
| 27 | https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-announces-555-million-private-placement | Whois | bicycletherapeutics.com |
| 28 | https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-announces-555-million-private-placement | Whois | bicycletherapeutics.com |
| 29 | https://www.businesswire.com/news/home/20240521592452/en/Indapta-Therapeutics-Awarded-4.5-Million-by-CPRIT-to-Advance-Clinical-Development-of-its-Allogenic-Natural-Killer-Cell-Therapy | Whois | businesswire.com |
| 30 | https://www.businesswire.com/news/home/20240521592452/en/Indapta-Therapeutics-Awarded-4.5-Million-by-CPRIT-to-Advance-Clinical-Development-of-its-Allogenic-Natural-Killer-Cell-Therapy | Whois | businesswire.com |
| 31 | https://ir.neumoratx.com/news-releases/news-release-details/neumora-therapeutics-announces-initiation-phase-2-study | Whois | neumoratx.com |
| 32 | https://ir.neumoratx.com/news-releases/news-release-details/neumora-therapeutics-announces-initiation-phase-2-study | Whois | neumoratx.com |
| 33 | https://elevate.bio/press-releases/elevatebio-announces-new-u-s-patents-for-lead-life-edit-crispr-systems-and-adenine-deaminases-enabling-advanced-gene-editing-techniques/ | Whois | elevate.bio |
| 34 | https://elevate.bio/press-releases/elevatebio-announces-new-u-s-patents-for-lead-life-edit-crispr-systems-and-adenine-deaminases-enabling-advanced-gene-editing-techniques/ | Whois | elevate.bio |
| 35 | https://www.linkedin.com/company/vertex-ventures-hc/ | Whois | linkedin.com |